ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

KYNB vs AKTX // EV/EBITDA & P/E VALUATION

Kyntra Bio Inc. (NASDAQ) VS. Akari Therapeutics plc ADS (NASDAQ) • 15-METRIC TALLY: KYNB 2 — AKTX 1
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (KYNB VS. AKTX) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC KYNB AKTX SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 91.40% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation ACTIVE — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin 68.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -65.00% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 4/9 2/9 +2.00 KYNB /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 26.9 47.0 -20.04 AKTX /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $18.8M $18.3M $547.1K KYNB /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR KYNB REV AKTX REV KYNB GROSS % AKTX GROSS % KYNB FCF AKTX FCF
FY 2025 $6.4M $0 91.4% — -$4.8M -$10.6M
FY 2024 $29.6M $0 47.5% — -$138.3M -$12.6M
FY 2023 $46.8M $367.9K — — -$315.0M -$16.4M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
KYNB // BETA —
AKTX // BETA —